Indicated to relieve
BOTH nasal and ocular
allergy symptoms

The first and only OTC intranasal corticosteroid (INS)* indicated to relieve itchy, watery eyes1-4

Same nasal allergy relief trusted for more than 20 years— with an ocular indication1,5

  • Significant relief of ocular itching and tearing due to nasal allergies6

Clinicians reported that FLONASE® Allergy Relief provided a >40% improvement of total ocular symptom scores (TOSS) in 7 days and a 50% improvement of TOSS in 14 days†,6

  • Day 7: 41.4% improvement for FLONASE® 200 µg QD (n=821) vs 26.4% for Placebo (n=822)
  • Day 14: 50% improvement for FLONASE® 200 µg QD (n=821) vs 31.3% for Placebo (n=822)

FLONASE® Allergy Relief contains fluticasone propionate, the #1-prescribed INS for allergic rhinitis, and delivers the same trusted, 24-hour prescription-strength relief.1,2,7 Because of the way it works, it may take several days for FLONASE® Allergy Relief, to reach maximum effect. Patients should be advised to take FLONASE® regularly, once a day.1,2,8

Recommended first-line, long-term

INSs such as FLONASE® Allergy Relief are recommended for initial and maintenance treatment of nasal allergies.§

  • First-Line Nasal Allergy Treatment
    Allergic Rhinitis and its Impact on Asthma (ARIA) treatment guidelines, issued in partnership with the World Health Organization, recommend INS treatments like FLONASE® as first-line treatment for allergic rhinitis, calling them “the most effective drugs”9,10
  • Long-Term Nasal Allergy Treatment
    INS treatments are recognized as the most effective, long-term treatment options for allergic rhinitis§11

*Glucocorticoid.

Based on recalculation of published data.

Based on IMS Health NPA Audit MAT June 2013–May 2014.

§The Joint Task Force on Practice Parameters (the American Academy of Allergy Asthma & Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology).

For some patients, 24-hour allergy relief begins with the first dose2

  • In some patients, FLONASE® starts to act on allergy symptoms in 2-4 hours1
  • Most patients will have achieved some nasal and ocular allergy relief in 12 hours1,8
  • Notable symptom improvement in allergy symptoms in 24-48 hours8
  • Maximum benefit achieved in 3-4 days in patients with allergic rhinitis1,2

For maximum benefit, advise patients with allergies to continue taking FLONASE® Allergy Relief for 3-4 days, then make it part of their daily routine.1,2

A well-established safety profile1

FLONASE® Allergy Relief is a corticosteroid with low (<1%) systemic absorption.1 Low-systemic absorption minimizes the potential for systemic side effects that are a concern with other corticosteroids used to treat allergic rhinitis, such as prednisone.12,13

FLONASE® Allergy Relief:

  • Is NOT associated with higher blood pressure and is not contraindicated in patients with2,12:
    • Hypertension
    • Heart disease
    • Diabetes
    • Liver disease
    • Kidney disease
  • Is NOT associated with anticholinergic side effects commonly associated with some other allergy medications. Does not cause1,14-17:
    • Drowsiness
    • Dry mouth
    • Nervousness
    • Dizziness
    • Sleeplessness

FLONASE® Allergy Relief has been trusted by doctors and pharmacists to relieve allergy symptoms for more than 20 years.1,2

Low Systemic Absorption

References:

  1. Data on file. GSK group of companies. 2014.
  2. FLONASE Drug Facts Label.
  3. Nasacort Drug Facts Label. 
  4. WebMD. Can nasal steroids ease allergy symptoms? http://www.webmd.com/allergies/nasal-steroids. Accessed October 14, 2014.
  5. US Food and Drug Administration. FDA approves first generic version of FLONASE [news release]. Silver Spring, MD: US Food and Drug Administration; February 22, 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108603.htm. Updated April 8, 2013. Accessed October 14, 2014.
  6. DeWester J, Philpot EE, Westlund RE, Cook CK, Rickard KA. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24(5):331-337.
  7. IMS Health Incorporated. IMS National Prescription Audit MAT June 2013-May 2014.
  8. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-1300.
  9. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy 2008;63(suppl 86):8-160. 
  10. Shinkwin CA. Guidelines in the management of allergic rhinitis. Bon Secours GP Study Day. January 28, 2012.
  11. Wallace DV, Dykewicz MS, Bernstein DI, et al, eds. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 suppl):S1-S84. 
  12. Greiner AN, Meltzer EO. Overview of the treatment of allergic rhinitis and nonallergic rhinopathy. Proc Am Thorac Soc. 2011;8(1):121-131.
  13. MedlinePlus. Prednisone. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601102.html. Accessed April 1, 2014. 
  14. MedlinePlus. Clemastine. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682542.html. Accessed April 1, 2014.
  15. MedlinePlus. Diphenhydramine. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682539.html. Accessed April 1, 2014. 
  16. MedlinePlus. Chlorpheniramine. http://www.nlm.nih.gov/ medlineplus/druginfo/meds/a682543.html. Accessed April 1, 2014.
  17. MedlinePlus. Pseudoephedrine. http://www.nlm.nih.gov/medlinepous/druginfo/meds/a682619.html. Accessed April 1, 2014.